## Mi Young Jeon

## List of Publications by Citations

Source: https://exaly.com/author-pdf/4301507/mi-young-jeon-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27 193 8 13 g-index

32 259 4.5 avg, IF L-index

#	Paper	IF	Citations
27	Long-term outcomes after noncurative endoscopic resection of <code>Tearly</code> gastric cancer: the optimal time for additional endoscopic <code>Ireatment</code> . <code>Gastrointestinal Endoscopy</code> , 2018, 87, 1003-1013.e2	5.2	30
26	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1221-1229	4	25
25	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , <b>2018</b> , 38, 676-686	7.9	20
24	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , <b>2017</b> , 11, 268-276	8.8	18
23	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 283-293	6.9	16
22	Additive endoscopic resection may be sufficient for patients with a positive lateral margin after endoscopic resection of learly gastric cancer. <i>Gastrointestinal Endoscopy</i> , <b>2017</b> , 86, 849-856	5.2	14
21	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , <b>2018</b> , 38, 1655	5-7:863	13
20	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , <b>2020</b> , 14, 626-635	4.8	10
19	Transarterial Chemoembolization in Treatment-NaWe and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3660-3668	4	6
18	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 316-322	3.4	5
17	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
16	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , <b>2019</b> , 14, e0214613	3.7	4
15	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 134	17 <sup>5</sup> 1 <sup>2</sup> 356	5 4
14	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , <b>2017</b> , 11, 693-701	4.8	4
13	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232186	3.7	3
12	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 295-304	6.9	3
11	Diagnostic Performance of Serum Asialo-II-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , <b>2019</b> , 74, 341-348	0.6	3

## LIST OF PUBLICATIONS

10	Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2020</b> , 158, 2310-2311	13.3	2
9	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 739-747	2.2	2
8	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 932-940	3.4	1
7	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , <b>2020</b> , 14, 477-485	4.8	1
6	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , <b>2021</b> , 39, 274-283	2.1	0
5	Response. Gastrointestinal Endoscopy, <b>2018</b> , 88, 972-973	5.2	
5 4	Response. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 88, 972-973  A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea <b>2020</b> , 15, e0232186	5.2	
	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea	5.2	
4	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea <b>2020</b> , 15, e0232186  A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea	5.2	